0 8

Cited 0 times in

RNA-seq Reveals Transcriptomic Differences in Inflamed and Noninflamed Intestinal Mucosa of Crohn's Disease Patients Compared with Normal Mucosa of Healthy Controls

Authors
 Sung Noh Hong  ;  Je-Gun Joung  ;  Joon Seol Bae  ;  Chan Soo Lee  ;  Ja Seol Koo  ;  Soo Jung Park  ;  Jong Pil Im  ;  You Sun Kim  ;  Ji Won Kim  ;  Woong Yang Park  ;  Young-Ho Kim 
Citation
 Inflammatory Bowel Diseases, Vol.23(7) : 1098-1108, 2017 
Journal Title
 Inflammatory Bowel Diseases 
ISSN
 1078-0998 
Issue Date
2017
MeSH
Adult ; Case-Control Studies ; Crohn Disease/genetics* ; Crohn Disease/immunology ; Crohn Disease/pathology ; Female ; High-Throughput Nucleotide Sequencing/methods* ; Humans ; Inflammation/diagnosis* ; Inflammation/etiology ; Inflammation Mediators/metabolism* ; Intestinal Mucosa/immunology ; Intestinal Mucosa/metabolism* ; Intestinal Mucosa/pathology ; Male ; Transcriptome*
Abstract
BACKGROUND: Aberrant gene expression in the gut mucosa might contribute to the initiation and progression of Crohn's disease (CD). RNA sequencing (RNA-seq) provides precise measurements of expression levels of transcripts and their isoforms. The aim of this study was to use RNA-seq to investigate transcriptomic differences and identify significantly differentially expressed transcripts in inflamed and noninflamed intestinal mucosa of CD patients. METHODS: RNA-seq was performed on 13 pairs of inflamed and noninflamed intestinal mucosa from 13 CD patients and on sex-matched normal mucosa of 13 healthy controls. Significantly differentially expressed transcripts were validated by immunohistochemistry, quantitative reverse transcriptase polymerase chain reaction, and enzyme-linked immunosorbent assay. RESULTS: RNA-seq revealed genome-wide transcriptomic differences between normal mucosa, noninflamed, and inflamed CD mucosa. Among 950 differentially expressed genes, 19 were up- or downregulated (upregulation: ANGPT2, CHN1, CPXM1, CPZ, CXCL1, FCN3, GJC1, HSD11B1, LZTS1, MEOX1, MMP12, PLA1A, SERPINE1, SGIP1, and TRPC4; downregulation: FAM189A1, PDE6A, SLC38A4, and HMGCS2) with statistical significance (p < 0.01 and q < 0.05). Among them, CXCL1 exhibited the highest fold change between groups. Immunohistochemistry for CXCL1 revealed no expression in normal mucosa, slightly increased expression in noninflamed CD mucosa, and highly increased expression in inflamed CD mucosa. Quantitative reverse transcriptase polymerase chain reaction showed that CXCL1 expression was significantly associated with epithelial damage, increased infiltration of polymorphonuclear leukocytes, and submucosal fibrosis. Serum CXCL1 concentration measured by enzyme-linked immunosorbent assay was better correlated with CD activity index (r = 0.660) than with C-reactive protein (r = 0.204). CONCLUSIONS: RNA-seq revealed transcriptomic differences between normal mucosa, noninflamed CD mucosa, and inflamed CD mucosa. Intestinal and serum CXCL1 was substantially increased with CD activity and can be used as a potential biomarker of CD.
URI
http://ir.ymlib.yonsei.ac.kr/handle/22282913/161391
DOI
10.1097/MIB.0000000000001066
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
박수정(Park, Soo Jung)
사서에게 알리기
  feedback
Full Text
https://academic.oup.com/ibdjournal/article/23/7/1098/4561113
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse